《新股消息》傳商湯科技最快年底前赴港上市
據路透旗下《IFR》引述消息指,內地最大人工智能公司商湯科技計劃最快年底前來港上市,同時亦會繼續推動在A股上市。據悉公司最近就來港上市與內部及外部人士進行了討論,消息人士指公司對在香港及上海兩地上市持開放態度,但目前未知會否兩地同時上市。
消息指科創板是商湯上市的最理想地點,但由於內地監管機構對科創板上市監管較緊,或會令商湯上市需要更長時間。
軟銀、淡馬錫、阿里(09988.HK)及高通均有份投資商湯科技,去年7月公司據報正尋求15億美元融資,當時估值約為100億美元,而今年1月內地傳媒報道公司新一輪融資時估值已達120億美元,公司發言人則拒絕評論。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.